Neutralizing type-I interferon autoantibodies are associated with delayed viral clearance and intensive care unit admission in patients with COVID-19

Michael S Abers1, Lindsey B Rosen1, Ottavia M Delmonte1, Elana Shaw1, Paul Bastard2,3,4, Luisa Imberti4, Virginia Quaresima4, Andrea Biondi5, Paolo Bonfanti6, Riccardo Castagnoli1,7, Jean-Laurent Casanova2,3,8,9, Helen C Su1,a, Luigi D Notarangelo1,a, Steven M Holland1,a & Michail S Lionakis1,a

1 Laboratory of Clinical Immunology & Microbiology, National Institute of Allergy & Infectious Diseases, National Institutes of Health, Bethesda, MD, USA
2 Laboratory of Human Genetics of Infectious Diseases, Necker Branch, INSERM U1163, Necker Hospital for Sick Children, Paris, France
3 Imagine Institute, University of Paris, Paris, France
4 CREA Laboratory, Diagnostic Department, ASST Spedali Civili di Brescia, Brescia, Italy
5 Pediatric Department and Centro Ricerca M. Tettamanti, Fondazione MBBM-Ospedale San Gerardo, University of Milano-Bicocca, Monza, Italy
6 Department of Infectious Diseases, San Gerardo Hospital, University of Milano-Bicocca, Monza, Italy
7 Department of Pediatrics, Fondazione IRCCS Policlinico San Matteo, University of Pavia, Pavia, Italy
8 St. Giles Laboratory of Human Genetics of Infectious Diseases, Rockefeller Branch, The Rockefeller University, New York, NY, USA
9 Howard Hughes Medical Institute, New York, NY, USA

Abstract
Type-I interferons (IFNs) mediate antiviral activity and have emerged as important immune mediators during coronavirus disease 19 (COVID-19). Several lines of evidence suggest that impaired type-I IFN signaling may predispose to severe COVID-19. However, the pathophysiologic mechanisms that contribute to illness severity remain unclear. In this study, our goal was to gain insight into how type-I IFNs influence outcomes in patients with COVID-19. To achieve this goal, we compared clinical outcomes between 26 patients with neutralizing type-I IFN autoantibodies (AAbs) and 192 patients without AAbs who were hospitalized for COVID-19 at three Italian hospitals. The presence of circulating AAbs to type-I IFNs was associated with an increased risk of admission to the intensive care unit and a delayed time to viral clearance. However, survival was not adversely affected by the presence of type-I IFN AAbs. Our findings provide further support for the role of type-I IFN AAbs in impairing host antiviral defense and promoting the development of critical COVID-19 pneumonia in severe acute respiratory syndrome coronavirus 2-infected individuals.

INTRODUCTION
Type-I interferons (IFNs) mediate antiviral immunity and exert other pleiotropic immune effects. Impaired type-I IFN responses have been identified in patients with severe coronavirus disease 19 (COVID-19), suggesting that type-I IFNs play a critical role against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).1,2

Keywords
Immunological deficiency syndromes, infectious diseases, innate immunity, translational immunology, viral infection

Correspondence
Michail S Lionakis, Laboratory of Clinical Immunology & Microbiology, National Institute of Allergy & Infectious Diseases, National Institutes of Health, Building 10, Room 12C103A, Bethesda, MD 20892, USA.
E-mail: lionakism@mail.nih.gov

Received 7 June 2021;
Revised 21 July 2021;
Accepted 23 July 2021

doi: 10.1111/icb.12495

Immunology & Cell Biology 2021; 99: 917–921
neutralizing AAbs against type-I IFNs in a subset of patients with life-threatening COVID-19 pneumonia has been replicated by several groups.2,6,7

Our original report did not examine the detailed clinical course of COVID-19 in patients harboring neutralizing AAbs against type-I IFNs beyond severity of SARS-CoV-2 infection.3 Furthermore, that study focused on patients with life-threatening infection, excluding less severe cases of COVID-19 who nonetheless required hospitalization. In the present study, we sought to determine the influence of AAbs to type-I IFNs on clinical outcomes in patients hospitalized for COVID-19.

RESULTS

We included 218 patients with COVID-19 in this study. Severity of illness was classified as critical in 135 patients (61.9%), severe in 44 (17.9%) and mild/moderate in 39 (20.2%). Of note, the 135 patients with critical COVID-19 were included in our previous report.3 Neutralizing AAbs to type-I IFNs were detected in 26 patients (11.9%), most of whom (17 patients) harbored AAbs to both IFNα and IFNβ (Supplementary figure 1). AAbs to IFNβ were detected in a single patient who also had AAbs to both IFNα and IFNβ. Clinical characteristics were compared between AAb-positive (AAb+) and AAb-negative (AAb−) patients (Supplementary table 1). The presence of AAbs was associated with male sex and severity of illness, whereas age and medical comorbidities did not significantly differ between the two groups in this cohort. The incidence of thrombotic complications was comparable between AAb+ and AAb− patients (Supplementary table 1). The proportion of patients who received anticoagulation or immunomodulatory medications such as corticosteroids and tocilizumab was not significantly different between AAb+ and AAb− patients (Supplementary table 1). AAb+ patients were significantly more likely to require invasive mechanical ventilation compared with AAb− patients (65.4% versus 29.9%, respectively; P = 0.001). Similarly, the proportion of patients who developed bacterial infections during the course of hospitalization was significantly greater in AAb+ (30.8%) versus AAb− (5.5%) patients (P < 0.001; Supplementary table 1).

Sufficient information to calculate the time to viral clearance was available in 119 patients, including 17 AAb+ patients and 102 AAb− patients. The median number of samples per patient did not differ between AAb+ and AAb− patients [median (interquartile range) 4 (3–5) versus 3 (2–4), respectively, P = 0.09]. The presence of neutralizing AAbs to type-I IFNs was associated with a markedly delayed time to viral clearance of SARS-CoV-2, as modeled by Cox proportional hazards [hazard ratio, 0.24; 95% confidence interval, 0.07–0.77; log-rank P = 0.003; Figure 1a]. The mean time to viral clearance in the overall cohort was 15 days. By contrast, the mean time to viral clearance was 24 days in AAb+ patients. This finding was particularly striking in patients admitted to the intensive care unit (ICU) (Figure 1b), with 100% of AAb-positive ICU patients remaining PCR positive 4 weeks after hospital admission. In addition, AAb positivity was associated with more severe infection (Figure 1c) and an increased risk for ICU admission during the first 15 days of hospitalization (Figure 1d; hazard ratio, 2.59; 95% confidence interval, 1.43–4.69; P = 0.004). Notably, although ICU admission was associated with greater mortality in the entire cohort of 218 patients (Figure 1e; hazard ratio, 2.35; 95% confidence interval, 1.14–4.85; P = 0.02), the presence of AAbs was not associated with patient survival (Figure 1f; hazard ratio, 0.64; 95% confidence interval, 0.22–1.81; P = 0.37), a finding that was consistent regardless of patient sex or ICU status (Supplementary figure 2).

DISCUSSION

Previous studies have shown that patients with AAbs against type-I IFNs have a predilection for developing life-threatening COVID-19.3,6,7 In addition, most patients with autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy/autoimmune polyglandular syndrome type-1,8 who carry neutralizing AAbs against type-I IFNs, are at risk for severe hypoxemic COVID-19 pneumonia.5,9 Initial reports of exogenous administration of IFNβ or plasma exchange in these patients, or IFNα2 in those with inborn errors of type-I IFN immunity, during the early nonhypoxemic phase of COVID-19 have provided promising results.4,5,10,11 The identification of type-I IFN AAbs in a sizable proportion of patients with severe COVID-19 in conjunction with the observation that the overwhelming majority of AAbs to type-I IFNs in patients with COVID-19 are directed against IFNα and/or IFNβ but not IFNβ provide a compelling rationale for the preferential investigation of IFNβ over IFNα in future clinical studies.2–7

While prior studies have established that patients with defects in the type-I IFN signaling pathway are predisposed to severe COVID-19,1,3 the pathophysiologic mechanisms that contribute to this enhanced illness severity remain unclear. We now show that patients with type-I IFN AAbs have delayed viral clearance contributing to the greater likelihood of developing critical COVID-19 pneumonia requiring ICU admission and mechanical ventilation. However, despite their increased morbidity, these patients surprisingly did not have an increased risk of death in our cohort. Several factors may account for
Neutralizing type-I interferon autoantibodies in COVID-19

Figure 1. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) clearance, admission to the intensive care unit (ICU) and survival in coronavirus disease 19 (COVID-19) patients with versus without autoantibodies (AAbs) to type-I interferons (IFNs). (a) Proportion of all patients testing positive for SARS-CoV-2 by PCR nasal swab test during the course of illness in a subset of patients with (n = 17) versus without (n = 102) AAbs to type-I IFNs. (b) Proportion of patients testing positive for SARS-CoV-2 by PCR nasal swab test during the course of illness in a subset of patients who required ICU care with (n = 11) versus without (n = 50) AAbs to type-I IFNs. (c) Severity of illness in patients with (n = 26) versus without (n = 192) AAbs to type-I IFNs. P = 0.012 by a Chi-squared test. (d) Cumulative incidence of ICU admission during the first 2 weeks of hospitalization in patients with (n = 25, including 3 admitted to ICU within 24 h of hospitalization) versus without (n = 190, including 16 admitted to ICU within 24 h of hospitalization) AAbs to type-I IFNs. Data on the timing of ICU admission relative to hospital admission were not available for three patients. (e) Kaplan–Meier plot displaying survival during the 10-week period following hospital admission in patients admitted to the ICU (n = 75) versus those not admitted to the ICU (n = 143). (f) Kaplan–Meier plot displaying survival during the 10-week period following hospital admission in patients with (n = 26) versus without (n = 192) AAbs to type-I IFNs. *No. at risk* in panels a–c refers to the number of patients in each group [AAb positive (AAb+) or AAb negative (AAb–)] who were alive at the specified time point. CI, confidence interval.

the lack of association between survival and the presence of neutralizing anti-type-I IFN antibodies. In particular, coordination between humoral and cellular adaptive immune responses has been shown to play a critical role in determining COVID-19 severity and outcome.12 Moreover, while a lack of type-I IFN signaling during early infection is clearly detrimental for SARS-CoV-2 containment, type-I IFNs may contribute to secondary inflammation during the late hyperinflammatory stage of COVID-19. Furthermore, in addition to immunologic factors, a variety of clinical and demographic characteristics, most notably patient age and the presence of comorbid conditions, play a critical role in influencing clinical outcomes. However, we did not detect differences in age or the prevalence of comorbid conditions in patients with versus without AAbs. Importantly, this does
Characterization was performed as previously described. Continuous variables were compared using a Mann-Whitney test. Categorical variables were compared by the Fisher exact test (when the expected number of observations in any group was < 5) or a Chi-squared test. Patient survival, time to viral clearance and time to ICU admission since hospital admission were modeled using univariate Cox proportional hazards regression; groups were compared using the log-rank test. For all analyses, statistical significance was defined as \( P < 0.05 \). Data were analyzed using R version 4.0.4 (R Foundation, Vienna, Austria).

ACKNOWLEDGMENTS

This work was supported by the Division of Intramural Research of the NIAID, NIH. The Laboratory of Human Genetics of Infectious Diseases is supported by the Howard Hughes Medical Institute, the Rockefeller University, the St. Giles Foundation, the National Institutes of Health (NIH) (R01AI088364), the National Center for Advancing Translational Sciences (NCATS), NIH Clinical and Translational Science Award (CTSA) program (UL1 TR001866), a Fast Grant from Emergent Ventures, Mercurius Center at George Mason University, the Yale Center for Mendelian Genomics and the GSP Coordinating Center funded by the National Human Genome Research Institute (NHGRI) (UM1HG006504 and U24HG008956), the French National Research Agency (ANR) under the "Investments for the Future” program (ANR-10-IAHU-01), the Integrative Biology of Emerging Infectious Diseases Laboratory of Excellence (ANR-10-LABX-62-IBEID), the French Foundation for Medical Research (FRM) (EQU201903007798), the FRM and ANR GENCOVid project, ANRS-COV05, the Square Foundation, Grandir - Fonds de solidarité pour l’enfance, the SCOR Corporate Foundation for Science, Institut National de la Santé et de la Recherche Médicale (INSERM) and the University of Paris. ASST Spedali Civili di Brescia and IRB of Fondazione IRCCS Policlinico San Matteo received a grant from Regione Lombardia, Italy (project “Risposta immune in pazienti con COVID-19 e co-morbilità”). PB is supported by the MD-PhD program of the Imagine Institute (with the support of the Fondation Bettencourt-Schueller).

CONFLICT OF INTEREST

The authors have no conflicts of interest to disclose.

AUTHOR CONTRIBUTIONS

Michael S Abers: Conceptualization; Data curation; Formal analysis; Investigation; Methodology; Software; Visualization; Writing-original draft; Writing-review & editing. Lindsey B Rosen: Data curation; Investigation. Ottavia M Delmonte: Data curation; Resources. Elana Shaw: Data curation; Investigation. Paul Bastard: Data curation; Investigation. Luisa Imberti: Data curation; Funding acquisition. Virginia Quaresima: Data curation; Funding acquisition. Andrea Biondi: Data curation; Funding acquisition. Paolo Bonfanti: Data curation; Funding acquisition. Riccardo Castagnoli: Data curation; Funding acquisition; Writing-review & editing. Jean-Laurent Casanova: Funding acquisition; Resources; Writing-review & editing. Helen C Su: Resources; Writing-review & editing. Luigi D Notarangelo: Funding acquisition; Project administration; Resources. Steven M Holland: Conceptualization; Funding acquisition; Project administration; Resources. Michail S
Lionakis: Conceptualization; Funding acquisition; Investigation; Supervision; Writing-original draft; Writing-review & editing.

DATA AVAILABILITY STATEMENT
Data are available upon request.

REFERENCES
1. Zhang Q, Bastard P, Liu Z, et al. Inborn errors of type I IFN immunity in patients with life-threatening COVID-19. Science 2020; 370: eabd4585.
2. van der Wijst MVS, Hartoularos GC, Bastard P, et al. Longitudinal single-cell epitope and RNA-seq reveals the immunological impact of type 1 interferon autoantibodies in critical COVID-19. Sci Transl Med 2021. https://doi.org/10.1101/2021.03.09.434529, in press.
3. Bastard P, Rosen LB, Zhang Q, et al. Autoantibodies against type I IFNs in patients with life-threatening COVID-19. Science 2020; 370: eabd4585.
4. Bastard P, Levy R, Henriquez S, Bodemer C, Szwebel TA, Casanova JL. Interferon-β therapy in a patient with incontinentia pigimeti and autoantibodies against type I IFNs infected with SARS-CoV-2. J Clin Immunol 2021; 41: 931–933.
5. Bastard P, Orlova E, Sozaeva L, et al. Preexisting autoantibodies to type I IFNs underlie critical COVID-19 pneumonia in patients with APS-1. J Exp Med 2021; 218: e20210554.
6. Koning R, Bastard P, Casanova JL, et al. Autoantibodies against type I interferons are associated with multi-organ failure in COVID-19 patients. Intensive Care Med 2021; 47: 704–706.
7. Troya J, Bastard P, Planas-Serra L, et al. Neutralizing autoantibodies to type I IFNs in >10% of patients with severe COVID-19 pneumonia hospitalized in Madrid, Spain. J Clin Immunol 2021; 41: 914–922.
8. Constantine GM, Lionakis MS. Lessons from primary immunodeficiencies: autoimmune regulator and autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy. Immunol Rev 2019; 287: 103–120.
9. Meisel C, Akbil B, Meyer T, et al. Mild COVID-19 despite autoantibodies against type I IFNs in autoimmune polyendocrine syndrome type 1. J Clin Invest 2021; 131: e150867.
10. Levy R, Bastard P, Lanternier F, Lecuit M, Zhang SY, Casanova JL. IFN-α2a therapy in two patients with inborn errors of TLR3 and IRF3 infected with SARS-CoV-2. J Clin Immunol 2021; 41: 26–27.
11. de Prost N, Bastard P, Arrestier R, et al. Plasma exchange to rescue patients with autoantibodies against type I interferons and life-threatening COVID-19 pneumonia. J Clin Immunol 2021; 41: 536–544.
12. Rydzynski Moderbacher C, Ramirez SI, Dan JM, et al. Antigen-specific adaptive immunity to SARS-CoV-2 in acute COVID-19 and associations with age and disease severity. Cell 2020; 183: 996–1012.
13. Abers MS, Delmonte OM, Ricotta EE, et al. An immune-based biomarker signature is associated with mortality in COVID-19 patients. JCI Insight 2021; 6: e144455.

SUPPORTING INFORMATION
Additional supporting information may be found online in the Supporting Information section at the end of the article.

© 2021 Australian and New Zealand Society for Immunology, Inc. This article has been contributed to by US Government employees and their work is in the public domain in the USA.